Skip to main content

OraSure Tech Value Stock - Dividend - Research Selection

Orasure tech

ISIN: US68554V1089 , WKN: 881351

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians\' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


OraSure Technologies: Outlook Is More Than Just Covid Testing

OraSure Technologies beats earnings expectations, benefiting from rising demand for broader infectious disease diagnostics amid declining COVID-19 test sales.

Top 5 Health Care Stocks That May Collapse In November

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Returns At OraSure Technologies (NASDAQ:OSUR) Appear To Be Weighed Down

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

OraSure to Participate in Upcoming Investor Conferences

BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences: Stephens Annual Investment Conference on Wednesday, November 15, with a Q&A session scheduled for 2 p.m. ETEvercore ISI Annual HealthCONx Conference on Tuesday, November 28, with

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

If you’re a fan of the hit TV show Shark Tank, you’ve probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination. In the field of finance, they are very real and coveted by venture investors looking for promising enterprises and valuations. The term “unicorn” in these contexts refers to privately owned companies whose valuations exceed the golden figure of $1 billion, and healthcare stocks are among the elite

OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Call Transcript

OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Call Transcript November 7, 2023 OraSure Technologies, Inc. beats earnings expectations. Reported EPS is $0.15, expectations were $0.07. Operator: Good day, and thank you for standing by. Welcome to the OraSure Technologies Inc 2023 Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only […]

Q3 2023 OraSure Technologies Inc Earnings Call

Q3 2023 OraSure Technologies Inc Earnings Call

Commit To Purchase OraSure Technologies At $5, Earn 20.2% Annualized Using Options

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

J.P. Morgan Remains a Hold on Orasure Technologies (OSUR)

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

OraSure Technologies (OSUR) Tops Q3 Earnings and Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 285.71% and 19.36%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?